Literature DB >> 23592281

Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.

Ning Zhang1, Lan Dai, Yanfei Qi, Wen Di, Pu Xia.   

Abstract

Combination therapy with different anticancer drugs has been proven to be an effective strategy for the treatment of various types of cancers, including ovarian cancer. We have previously reported that FTY720 exhibited potent cytotoxic effects in ovarian cancer cells through the necrotic pathway, which differs from the killing effect of cisplatin (CDDP). In the present study, we report that the combination of FTY720 with CDDP yields an unexpected antagonistic effect towards the cytotoxicity of CDDP in a variety of ovarian cancer cell lines, including both CDDP-sensitive and -resistant cells. The antagonistic activity of FTY720 appears ascribable to its effect in autophagy induction. A significant increase in baseline autophagy was observed in CDDP-resistant ovarian cancer cells, compared with the sensitive cells. Blockade of autophagy by either a pharmacological inhibitor (3-MA) or siRNA-mediated knockdown of autophagic gene expression enhances CDDP-induced apoptotic cell death. Notably, by inhibiting autophagy, 3-MA can convert the combination of FTY720 with CDDP from an antagonistic into an additive effect towards killing ovarian cancer cells. Collectively, the findings suggest that a combination of an autophagy regulator with the CDDP-based regime could effectively modulate its efficacy for the treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592281     DOI: 10.3892/ijo.2013.1906

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

Review 1.  Targeting PP2A in cancer: Combination therapies.

Authors:  Sahar Mazhar; Sarah E Taylor; Jaya Sangodkar; Goutham Narla
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-01       Impact factor: 4.739

2.  FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.

Authors:  Kelly M Kreitzburg; Samuel C Fehling; Charles N Landen; Tracy L Gamblin; Rebecca B Vance; Rebecca C Arend; Ashwini A Katre; Patsy G Oliver; Robert C A M van Waardenburg; Ronald D Alvarez; Karina J Yoon
Journal:  Cancer Lett       Date:  2018-08-16       Impact factor: 8.679

3.  xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

Authors:  Peng Zhang; Wei Wang; Zhenhui Wei; L I Xu; Xuanning Yang; Yuanhong DU
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

4.  Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.

Authors:  Alexandria N Young; Denisse Herrera; Andrew C Huntsman; Melissa A Korkmaz; Daniel D Lantvit; Sarmistha Mazumder; Shamalatha Kolli; Christopher C Coss; Salane King; Hongyan Wang; Steven M Swanson; A Douglas Kinghorn; Xiaoli Zhang; Mitch A Phelps; Leslie N Aldrich; James R Fuchs; Joanna E Burdette
Journal:  Mol Cancer Ther       Date:  2018-07-17       Impact factor: 6.261

5.  Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.

Authors:  Ning Zhang; Jia-Ning Fu; Ting-Chao Chou
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

Review 6.  PP2A: The Wolf in Sheep's Clothing?

Authors:  Maeve Kiely; Patrick A Kiely
Journal:  Cancers (Basel)       Date:  2015-04-10       Impact factor: 6.639

7.  Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.

Authors:  C Kao; A Chao; C-L Tsai; W-C Chuang; W-P Huang; G-C Chen; C-Y Lin; T-H Wang; H-S Wang; C-H Lai
Journal:  Cell Death Dis       Date:  2014-11-06       Impact factor: 8.469

8.  Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.

Authors:  Hyun-Soo Kim; Gun Yoon; Ji-Yoon Ryu; Young-Jae Cho; Jung-Joo Choi; Yoo-Young Lee; Tae-Joong Kim; Chel-Hun Choi; Sang Yong Song; Byoung-Gie Kim; Duk-Soo Bae; Jeong-Won Lee
Journal:  Oncotarget       Date:  2015-09-29

9.  Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.

Authors:  Ryoko Takahashi; Seiji Mabuchi; Mahiru Kawano; Tomoyuki Sasano; Yuri Matsumoto; Hiromasa Kuroda; Katsumi Kozasa; Kae Hashimoto; Kenjiro Sawada; Tadashi Kimura
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 10.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.